Start with lower doses and increase as needed and tolerated. Measure Karbinal ER with an accurate milliliter measuring device.
[see Warnings and Precautions (5.5)] Adults and Adolescents 12 years of age and older: 7.5 m L to 20 m L (6 to 16 mg) every 12 hours Children 2 to 11 years of age (approximately 0.2 to 0.4 mg/kg/day): 2 to 3 years: 3.75 m L to 5 m L (3 to 4 mg) every 12 hours 4 to 5 years: 3.75 m L to 10 m L (3 to 8 mg) every 12 hours 6 to 11 years: 7.5 m L to 15 m L (6 to 12 mg) every 12 hours HOW SUPPLIED: Extended-release oral suspension containing 4 mg carbinoxamine maleate per 5 m L Adult (usual): 4 mg po every 4 to 6 hrs; maximum dose: 24 mg/day.Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.Dosage - Oral: Children 6-11 years: 30 mg twice daily Children /= 6 years and Adults: 10 mg once daily Elderly: Peak plasma levels are increased; elimination half-life is slightly increased; specific dosing adjustments are not available Dosage adjustment in renal impairment: Clcr /= 6 years and Adults: 10 mg every other day Supplied Syrup (Claritin®): 1 mg/m L (120 m L) [contains sodium benzoate; fruit flavor] Tablet (Alavert™, Claritin®, Claritin® Hives Relief; Tavist® ND): 10 mg Tablet, rapidly-disintegrating: 10 mg Alavert™: 10 mg [contains phenylalanine 8.4 mg/tablet] Claritin® Redi Tabs®: 10 mg [mint flavor] Dimetapp® Children's ND: 10 mg [contains phenylalanine 8.4 mg/tablet] (pseudoephedrine 120mg fexofenadine 60mg).Dosing:: one tablet twice daily for adults and children 12 years of age and older (should be taken on an empty stomach).In addition one theory proposes that alcoholism risk is also associated with a larger stimulatory response to alcohol.
Please see package insert for additional information and possible updates.
The clinical significance of these findings is unknown.
In laboratory animals, no anticholinergic or alpha1-adrenergic blocking effects were observed.
In general, stimulatory effects are thought to be more rewarding than sedative effects, but this may not be true for anxiolytic effects which seem more closely related to sedation than stimulation.
The two major theories of how response to alcohol predicts risk for alcoholism both postulate that individuals at high risk for alcohol use disorders have a reduced sedative response to alcohol compared to individuals not at high risk.
Moreover, no sedative or other central nervous system effects were observed.